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1170-38 Performance of Cardiac Troponln I in the Exclusion of 
Myocardial Infarction in Patients With Advanced Renal 
Disease 
Peter A. McCullouoh, Richard M. Nowak, Craig Foreback, Steven Borzak, Glenn 
Tokarski, Michael C. Tomlanovich, Gordon Jacobsen, W. Douglas Weaver, Keisha R. 
Sandberg, James McCord, University of Missouri-Kansas City School of Medicine, 
Truman Medical Center, Kansas Ci~ Missouri, Henry Ford Heart and Vascular Institute, 
Detroit, Michigan. 
Background. Previous studies have demonstrated higher rates of false positive cardiac 
enzymes in patients with chronic renal disease who are evaluated for the presence of 
acute myocardial infarction (AMI). 
Method,=. Baseline renal function, and btinded determination of AMI by two cardiologists 
according to World Health Organization criteda were available for 808 patients in a pro- 
spective cardiac biomarker study, Patients, mean age 63.7, were evaluated in the emer- 
gency department for chest discomfort. Patients were stratified by corrected creatinine 
clearance into quartiles, and those with end-stage renal disease (ESRD) were consid- 
ered as a fifth comparison group. Over 99% were admitted to a chest pain unit or hospital 
bed. The overall rate of myocardial infarction was 8.00/o. 
Results. At 90 minutes, using a bedside point-of-care measurement of cardiac tropenin 
(c-Tnl), and a cut-off of 0.4 ng/ml, the negative predictive value was > 90% in all renal 
groups. There was no trend for higher rates of false positive c-Tnl in those with renal dys- 
function or ESRD who were ultimately determined not to have AMI (see figure). 
Conclusion. Use of a point-of-care measurement of c-Tnl at 90 minutes after presenta- 
tion is robust to the presence of renal dysfunction and excludes AMI with satisfactory per- 
formance in a rapid cardiac triage protocol. 
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1170-37 Heterogene i ty  of  Infarct Sizing in Non-ST Segment  
Elevation Acute Coronary Syndromes: Results From 
the EARLY Pi lot  Trial 
Matthew "1". Roe. Robert C. Chdstenson, Hongqiu Yang, Raymond Bahr, Francis M. 
Fasmire, Michael Mollod, E. Magnus Ohman, W. Bdan Gibler, Duke Clinical Research 
Institute, Durham, North Carolina, University of Maryland, Baltimore, Maryland. 
Background: Infarct size measurements have not been well described in patients with 
non-ST-segment elevation acute coronary syndromes (NSTE ACS). 
Methods: Patients presenting with NSTE ACS enrolled in the EARLY Pilot Trial had 
sedal creatine kinase(CK)-MB samples drawn at 0, 3, 6, 12, and 24 hours after random- 
ization in the Emergency Department (ED) to early vs. delayed treatment with eptffi- 
betide. 
Results: Collection of cardiac marker samples began a median of 8.3 hours (25 th, 75 th 
percentiles: 5.4, 11.9 hours) after the onset of ischemie symptoms in the 311 patients 
studied. The median peak CK-MB was 8.6 ng/ml (2.0, 39.7) - CK-MB ULN = 7 ng/ml. A 
total of 112 patients (36%) had sufficient CK-MB elevation over 24 hours to determine 
curve-fitting parameters of infarct size. The remaining patients' CK-MB data could not be 
curve-fitted due to declining CK-MB values from the baseline sample (22%), no signifi- 
cant CK-MB elevation (36%), late CK-MB elevation (3%), or insufficient sampling (3%). 
The median CK-MB area-under-the-curve over 24 hours was 740.5 ug/min/L (200.5, 
1871 ) in curve-fitted patients. 
Baseline Peak 
CK-MB 0-2X ULN 68.9% 60.8% 
CK-MB 2-5X U LN 10.1% 12.7% 
CK-MB > 5X ULN 21.0% 26.5% 
Conclusions: Infarct size measurements demonstrate marked variability in patients with 
NSTE ACS reflecting the hetereogeneity of this population. Improved strategies of rapid 
risk stratification are needed for patients with NSTE ACS to quantify the risk of subse- 
quent myocardial necrosis and guide therapeutic efforts to reduce infarct size. 
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1171-28 Is Left Ventricular Diastolic Function an Independent 
Determinant of Prognosis in Patients With an Acute 
Myocardial Infarction Treated with Thrombolysls? 
Miguel Quintana, Magnus Edner, Thomas Kahan, AIf Sollevi, Nina Rehnqvist, Paul 
Hjemdahl, Karo/inska Institutet Danderyd Hospital, Stockholm, Sweden, Huddinge 
University Hospital, Stockholm, Sweden. 
Background: Recent studies have suggested that signs of left ventdcular (LV) diastolic 
dysfunction may predict cardiac enlargement, and independently predict cardiovascular 
mortality after an acute myocardial infarction (AMI). However, the studies were small, 
which precludes generalization of the results. 
Methods: 520 pts (mean age 64±11 (SD) ys, 77% males) participating in the ATTACC 
(ATTenuation by Adenosine of Cardiac Complications) study underwent a 2D and Dop- 
pler echocardiography 5.+.2 days after hospitalization for an ST elevation AMI, treated by 
thrombolysis. LV diastolic function was assessed by pulsed wave Doppler of the mitral 
inflow (E and A wave velocities, E/A ratio and E wave deceleration time). LV systolic 
function was assessed by wall motion score index (WMSi) and LV ejection fraction (EF). 
A sequential multistep multivariate regression analysis was used to assess long-term 
cardiovascular (CV) death, and the occurrence of the composite end-point of CV death or 
non-fatal AMI. In the first step only clinical vadables (age, gender, previous AMI, hyper- 
tension, diabetes, cerebrovascular disease and smoking habits) were introduced in the 
model. In the second step, variables obtained during hospitalization (respiratory rate, 
heart rate and systolic blood pressure on admission, AMI localization by EKG and peak 
CK-MB isoenzyme value) were included. In the final step echocardiographic variables 
were introduced. 
Results: During a mean follow-up of 2.6 (range 2.1 - 3.2) ys 58 CV deaths (11%) 
occurred and 124 pts (24%) reached the composite end-point of CV death or non-fatal 
AMI. WMSi and LV EF were lower (P<0.001) in patients who had an event (15 vs. 17 
points, 0.36 vs. 0.44, respectively). However, all measures of LV diastolic function were 
similar in subjects who had a CV event and those who did not. In the final sequential mul- 
tistep multivariate regression analysis only age (P<0.001), previous hypertension 
(P<0.00f), WMSi (P=0.003), hypotension O n admission (P=O.03) and diabetes (P=0.04) 
were independent predictors of CV death. 
Conclusion: Only clinical variables and LV systolic function independently predicted CV 
death. LV diastolic function does not add prognostic information. 
1171-29 IS There a Gender Difference in the Risk of Arrhythmic 
Death After Acute Myocardial Infarction? An Insight 
From Contemporary Survival Studies 
Yee Guan YaP, Trinh Duong, Martin Bland, Marek Matik, Christian Torp-Pederson, Lars 
Kober, Stuart Connolly, Bradley Marchant, A. John Carom, St. George's Hospital Medical 
School, London, United Kingdom. 
Background: Arrhythmic death is the commonest mode of death after acute myocardial 
infarction (AMI) but the role of gender on the risk of arrhythmic death after AMI is 
unknown. Methods: We pooled the individual data on 3105 placebo patient (2471M, 
median age: 65 (23-92)) from E.M.LA.T., C.A.M.LA.T., S.W.O.R.D., T.R.A.C.E. and 
D.I.A.M.O.N.D.-M.I. with LVEF<40% or frequent ventricular ectopics. Survival was mea- 
sured from day 45 after MI to allow for different recruitment periods. Cox multiple regres- 
sion was used. Results: Among the 3105 patients, there were 488 deaths by 2 years 
(220 arrhythmic death (AD) & 172 non-arrhythmic ardiac death (NAD)). After adjusted 
for significant variables associated with either AD or NAD (age, previous MI, hyperten- 
sion, angina, systolic blood pressure, heart rate, NYHA class, LVEF & Q-wave), male 
patients were 1.7 times significantly more likely to die of AD than NAD compared to 
female patients (table). Female patients began with similar rates of AD and NAD but after 
first year, AD became the predominant mode of cardiac death. In contrast, AD remained 
higher than NAD in male patients at all time. Rates per 100 person-year at risk (AD: 
NAD): Up to 6 m (M= 7.48 : 5.06; F= 10.49 : 10.03); >6 - 12 m (M= 4.61 : 3.20; F= 1.96 : 
3.92); >12-18 m (M= 4.41 : 3.37; F= 4.05 : 4.50); >18-24 m (M= 4.47 : 2.38; F= 1.07 : 
4.27). Conclusion: Our study provides the first data that female gender appears protec- 
tive against AD at 24 months after MI. Such data is vital when stratifying patients for anti- 
arrhythmic therapy. 
Cause-specific 2-year Ratio of relative hazard P-value for interaction 
incidence (%); AD:NAD of AD:NAD; (95% CI) 
M 9.1 : 6.2 1.74 (1.04-2.91) 0.03 
F 7.2 : 9.5 1 
